Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,509Revenue $M91.1Net Margin (%)-246.9Altman Z-Score5.7
Enterprise Value $M7,276EPS $-0.4Operating Margin %-174.3Piotroski F-Score5
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-242.0Higher ROA y-yY
Price/Book9.010-y EBITDA Growth Rate %9.0Quick Ratio2.1Cash flow > EarningsY
Price/Sales71.35-y EBITDA Growth Rate %39.8Current Ratio2.2Lower Leverage y-yY
Price/Free Cash Flow45.0y-y EBITDA Growth Rate %--ROA % (ttm)-18.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-28.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M458ROIC % (ttm)-20.8Gross Margin Increase y-yY

Gurus Latest Trades with OPK

Number of guru portfolios checked: 68.
TickerupGuruDate Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OPKKen Fisher 2015-03-31 Buy $9.91 - $15.03
($13.01)
$ 16.3826%New holding29,200
OPKMario Gabelli 2014-09-30 Reduce$8.19 - $9.46
($8.79)
$ 16.3886%Reduce 26.67%11,000
OPKGeorge Soros 2014-06-30 Reduce-0.12%$8.01 - $9.71
($8.73)
$ 16.3888%Reduce 84.24%235,600
OPKGeorge Soros 2014-03-31 Add0.06%$7.58 - $9.96
($8.75)
$ 16.3887%Add 76.98%1,494,800
OPKGeorge Soros 2013-09-30 Buy 0.07%$7.18 - $9.24
($8.02)
$ 16.38104%New holding745,000
OPKMario Gabelli 2011-03-31 Reduce$3.48 - $4.83
($4.01)
$ 16.38308%Reduce 90.58%15,000
OPKMario Gabelli 2010-09-30 Add$2.07 - $2.6
($2.31)
$ 16.38609%Add 962.00%159,300
OPKMario Gabelli 2010-06-30 Reduce$1.87 - $2.55
($2.11)
$ 16.38676%Reduce 90.00%15,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OPK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


OPK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-07-08Buy7,200$16.56-1.09view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-07-07Buy5,400$16.64-1.56view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-07-06Buy3,600$16.071.93view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-07-02Buy9,000$16.131.55view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-06-29Buy7,200$15.624.87view
BARON ROBERT ADirector 2015-06-29Buy2,000$15.823.54view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-06-26Buy5,400$16.071.93view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-06-25Buy7,200$15.396.43view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-06-24Buy57,200$15.336.85view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2015-06-23Buy9,000$15.65view

Quarterly/Annual Reports about OPK:

News about OPK:

Articles On GuruFocus.com
my portfolio Jul 24 2015 
my portfolio Jul 24 2015 
Weekly CEO Buys Highlight: CLMS, OPK, ROVI, LPG, GAM Jul 13 2015 
Weekly CEO Buys Highlight: GPP, CLMS, ADC, SNR, OPK Jul 06 2015 
mio Jun 09 2015 
mio Jun 09 2015 
mio Jun 09 2015 
Oppenheimer Weighs in on Biotech Stocks: Opko Health, OvaScience Inc May 13 2015 
Weekly CEO Buys Highlight: OPK, CLMS, GFF, TCB, SFNC May 12 2015 
CNN To Use Drone Aviation Holding's Products For FAA Research May 08 2015 

More From Other Websites
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 Jul 30 2015
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 Jul 30 2015
FDA Accepts OPKO's New Drug Application for Rayaldee™ Jul 28 2015
FDA Accepts OPKO’s New Drug Application for Rayaldee™ Jul 28 2015
Opko Health: Why Recent Weakness Represents A Golden Buying Opportunity Jul 24 2015
OPKO's Prostate Cancer Hit Jul 23 2015
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources Jul 10 2015
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient... Jul 10 2015
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient... Jul 10 2015
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources Jul 10 2015
FuelCell Energy, Windstream And Others Insiders Have Been Buying Jul 07 2015
4 Stocks Rising on Unusual Volume Jul 07 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 05 2015
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements... Jul 02 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
3 Reasons Why Opko Health's Stock Could Soar Jul 01 2015
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts Jul 01 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK